Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14165607 | 0.95 | ALDH1A1 (0.42) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL3892858 | 0.93 | ALDH1A1 (0.45) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL14690688 | 0.91 | — | — | |
| Benzene SCHEMBL28175146 | 0.90 | ALDH1A1 (0.42) | USP2ALDH1A1LMNACYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL20531748 | 0.88 | USP2 (0.34) | USP2ALDH1A1LMNACYP1A2TSHR | |
| Oxalic Acid SCHEMBL14842438 | 0.86 | USP2 (0.33) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL14842130 | 0.81 | KDM4E (0.31) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL14845321 | 0.79 | USP2 (0.33) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL14845323 | 0.79 | USP2 (0.33) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL18131263 | 0.79 | MME (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-04-11 | — | — | US | disclosed |
| WO-2023209086-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| US-20230339976-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-10-26 | — | — | US | disclosed |
| EP-4192585-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023094305-A1 | PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3548495-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018102384-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
| US-20160030414-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | AUSPEX PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | CAMK1, CAMKK1, CAMK1D | USP2 3374/4885ALDH1A1 1512/4885LMNA 1251/4885 |
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | CYP1B1, CYP2D6, CYP1A1 | USP2 4069/4885ALDH1A1 130/4885LMNA 2244/4885 |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | USP2 3374/4885ALDH1A1 1512/4885LMNA 1251/4885 |
| US-20160030414-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | SLC18A2, ACAT2, SLC6A2 | USP2 2480/4885ALDH1A1 695/4885LMNA 2477/4885 |
| US-20230339976-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | USP2 1364/4885ALDH1A1 2681/4885LMNA 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.